Site icon Duncan Bucknell

Pharma & Biotech GWiR 20 February 2009 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

GSK floats patent pool for neglected diseases (Spicy IP) (Intellectual Property Watch) (IAM) (guardian.co.uk) (IPKat)

European Patent Office accepts traditional knowledge database from Indian government to help stop ‘biopiracy’ (Managing Intellectual Property) (Out-Law) (Intellectual Property Watch)

 
General

GSK floats patent pool for neglected diseases (Spicy IP) (Intellectual Property Watch) (IAM) (guardian.co.uk) (IPKat)

SPC seminar sound-track now available (The SPC Blog)

NVCA study shows decline in 2008 investment; BIO study predicts biotech rebound in 2009 (Patent Docs)

Generic patent challenges rose 19% in 2008 according to data compiled by Stanford Group analyst Adam Greene (Law360)

Brazil, HIV/AIDS and domestic patent policy (IP tango)

Brazil: Farming GMO and biotech inventions in Brazil (IP tango)

EU: EPO accepts traditional knowledge database from Indian government to help stop ‘biopiracy’ (Managing Intellectual Property) (Out-Law) (Intellectual Property Watch)

EU: Strong EU provisions on IP seen as threat to poor nations’ medicines access (Intellectual Property Watch)

India: New pricing rules for imported drugs (Spicy IP)

US: FDA orphan drug designations are on the rise (FDA Law Blog)

US: The future of biotechnology (Patent Docs)

 
Products

Cancidas (Caspofungin) – EU: Merck told to gets it paperwork in order in its application for extension of granted SPC (The SPC Blog)

Hytrin (Terazosin) – US: 9th Circuit finds genuine issues relating to possible Walker process fraud arising from counsel’s omissions in patent application process: Kaiser Foundation Health Plan, Inc v Abbott Laboratories, Inc (Intellectual Property Law Blog)

Januvia (Sitagliptin) – Netherlands: Closer reading shows Netherland Patent Office granted negative term SPC (The SPC Blog)

Lotrel (Amlodipine/Benazepril) – US: Novartis, Par settle patent suit over Lotrel (Law360)

Lunesta (Eszopiclone) – US: Teva and Cobalt file applications to produce generic versions of Sepracor’s Lunestra, alleging invalidity/unenforceability of Sepracor patent (GenericsWeb)

Opana (Oxymorphone) – US: Endo, Penwest reach settlement with Actavis in patent infringement suit over generic Opana (Law360)

Singulair (Montelukast) – US: Patent dispute between Merck and Teva over Singulair to be heard in federal court in Trenton on Monday (GenericsWeb)

Tarceva (Erlotinib) – India: Erlotinib pre-grant opposition: Minor modification and structural similarity not sufficient to establish obviousness (Patent Circle) (Patent Circle)

Zicam (Zinc gluconate) – US: Capricorn Pharma lodges amended complaint against Matrixx Initiative and Zicam over Zicam cold remedy claiming patent and trade mark infringement (Law360)

 

 

Exit mobile version